Our Approach


Team


CEO
Formerly: CRISPR, Pfizer, Kaleido, Millennium
Michael Bruce PhD has served as the CEO of Exo Therapeutics since early 2020. Dr Bruce has more than 20 years of drug discovery and development experience, including leadership of the development of marketed products including Bosulif and Nerlynx. Most recently, Dr Bruce was at Kaleido Biosciences (Nasdaq: KLDO) where he was a member of the deal roadshow team for the company’s IPO. Prior to Kaleido, Dr. Bruce was an early employee of CRISPR Therapeutics (Nasdaq: CRSP) where he oversaw product development and alliance management, including deals with Vertex and Bayer. Dr Bruce spent more than 12y at Wyeth and Pfizer in a variety of product development, portfolio management and clinical operations roles. Dr Bruce holds a PhD in organic chemistry from Stanford University and a BA in Chemistry from Williams College. Dr Bruce lives with his wife, a physician, and three school aged children, and entertains them with adequate guitar playing from time to time.
Formerly: CRISPR, Pfizer, Kaleido, Millennium

Senior Vice President, Platform & Discovery
Chris is the Senior Vice President of Platform and Discovery at Exo and oversees the company’s technology development and early drug discovery efforts. Trained as a synthetic chemist, Chris spent his early career at Cubist Pharmaceuticals discovering novel antibacterials and treatments for the host-side indications associated with life-threatening infection. His interest in novel research platforms began when he joined an early innovation team within Cubist that would eventually create an internal venture fund to deliver cutting-edge proof-of-concept research projects beyond Cubist’s traditional areas of focus. This interest would eventually lead him to Kaleido Biosciences, which he joined at its founding in 2015 to prove that chemical matter could change the structure and function of the human microbiome to treat severe disease. After six years, multiple financing rounds including a successful IPO, growth to over 100 employees, and four compounds delivered to clinical study, Chris left Kaleido to come to Exo and focus on building a new discovery platform. Chris holds a BSc in chemistry from MIT, a PhD from the University of Michigan, and took his post-doctoral training at The Scripps Research Institute.

Senior Vice President, Finance & Operations
Paul Schneider is Senior Vice President, Head of Finance and Operations at Exo Therapeutics. He has over 20 years of global financial, commercial, and operational experience in the life sciences industry. Prior to joining Exo Therapeutics, Paul served most recently as Senior Vice President, Finance at Casebia Therapeutics, where he was responsible for all finance and accounting, IT, investor relations and lab operations functions. Previously, he has held senior corporate finance positions at Aegerion Pharmaceuticals, Systagenix Wound Management, Shire Human Genetics Therapies, Inc. and Transkaryotic Therapies, Inc. Paul began his professional career at Coopers and Lybrand, LLP. He holds a Bachelor of Science in Accounting from Boston College and was licensed as a Certified Public Accountant in Massachusetts.

Executive Director, Drug Discovery
Ghotas is Executive Director of drug discovery at Exo Therapeutics. He has authored well over 50 peer-reviewed publications and patents in drug discovery and platform development including DNA Encoded Library (DEL) technology. His industrial career initiated at Vertex Pharmaceuticals, Cambridge, as a medicinal chemist where he was instrumental in discovery of first- and second-generation P38 MAP Kinase inhibitors and second-generation ICE-1 inhibitor clinical candidates. Prior to joining Exo, he was senior site manager and group leader at GSK, Waltham where he honed his expertise in library design and development, GSK DEL portfolio management, hit discovery and hit to lead efforts while pioneering Encoded Library Technology (ELT). Ghotas was a principal scientist and program co-leader for the sphingosine-1-phosphate (S1P) receptor agonist program which led to GSK799A clinical candidate upon GSK acquisition of Praecis Pharmaceuticals. Ghotas holds a PhD in organic chemistry from the University of Toronto and a BSc in biochemistry and MSc in bio-organic chemistry from the University of Waterloo, Canada.
Drug Discovery

Executive Director, Head of Biology
As Executive Director, Head of Biology, Shilpi is responsible for discovery and translational biology at Exo Therapeutics. Shilpi has over 15 years of experience in leading multiple aspects of drug discovery, target ID/ validation, pharmacology and translational sciences across academia, not-for-profit and biotech companies. Prior to joining Exo, Shilpi was head of Cell biology at X-Chem Pharmaceuticals, where she was responsible for setting up the cell biology function to support internal drug discovery portfolio focused on oncology, inflammation and rare diseases. Prior to X-Chem, Shilpi spent 6+ years at Constellation Pharmaceuticals, where most recently she was Associate Director and head of Discovery biology. She co-led the 2nd generation EZH2 inhibitor program (CPI-0209), currently in Ph.1 clinical trials. Prior to joining Constellation, Shilpi was a Research Investigator at Translational Genomics Research institute. She is well-published in the fields of cancer genomics, cellular signaling and identification and validation of new targets using high throughput technologies. Shilpi received a B.Sc. (Hons) in Biochemistry from Delhi University, an M.S. in Biotechnology and Ph.D. in Cancer Biology from All India Institute of Medical sciences. She completed her post-doctoral studies at the Sanford Burnham Institute and University of California, Irvine.
Head of Biology

Co-Founder
David R. Liu is the Richard Merkin Professor, Director of the Merkin Institute of Transformative Technologies in Healthcare, and Vice-Chair of the Faculty at the Broad Institute of Harvard and MIT; Thomas Dudley Cabot Professor of the Natural Sciences and Professor of Chemistry and Chemical Biology at Harvard University; and Howard Hughes Medical Institute Investigator.
Liu graduated first in his class at Harvard in 1994. He performed organic and bioorganic chemistry research on sterol biosynthesis under Professor E. J. Corey’s guidance as an undergraduate. During his Ph.D. research with Professor Peter Schultz at U. C. Berkeley, Liu initiated the first general effort to expand the genetic code in living cells. He earned his Ph.D. in 1999 and became Assistant Professor of Chemistry and Chemical Biology at Harvard University in the same year. He was promoted to Associate Professor in 2003 and to Full Professor in 2005. Liu became a Howard Hughes Medical Institute Investigator in 2005 and joined the JASONs, academic science advisors to the U.S. government, in 2009. Liu has earned several university-wide distinctions for teaching at Harvard, including the Joseph R. Levenson Memorial Teaching Prize, the Roslyn Abramson Award, and a Harvard College Professorship.
Liu has published >180 papers and is the inventor of >70 issued U.S. patents. His research accomplishments have earned distinctions including the Ronald Breslow Award for Biomimetic Chemistry, the American Chemical Society Pure Chemistry Award, the Arthur C. Cope Young Scholar Award, and awards from the Sloan Foundation, Beckman Foundation, NSF CAREER Program, and Searle Scholars Program. In 2016 he was named one of the Top 20 Translational Researchers in the world by Nature Biotechnology, and in 2017 was named to the Nature’s 10 researchers in world and to the Foreign Policy Leading Global Thinkers.
Professor Liu’s research integrates chemistry and evolution to illuminate biology and enable next-generation therapeutics. His major research interests include the engineering, evolution, and in vivo delivery of genome editing proteins such as base editors and prime editors to study and treat genetic diseases; the evolution of proteins with novel therapeutic potential using phage-assisted continuous evolution (PACE); and the discovery of bioactive synthetic small molecules and synthetic polymers using DNA-templated organic synthesis and DNA-encoded libraries. Base editing (named one of four 2017 Breakthrough of the Year finalists by Science), prime editing, PACE, and DNA-templated synthesis are four examples of technologies pioneered in his laboratory. He is the scientific founder or co-founder of seven biotechnology and therapeutics companies, including Editas Medicine, Pairwise Plants, Exo Therapeutics, Beam Therapeutics, and Prime Medicine.
Broad, HHMI
Founder, Editas, Beam, Prime
Richard Merkin Professor, Director of the Merkin Institute, Core Institute Member, and Vice-Chair of the Faculty, Broad Institute
Investigator, Howard Hughes Medical Institute
Thomas Dudley Cabot Professor of the Natural Sciences and Professor of Chemistry & Chemical Biology, Harvard University

Co-Founder
Alan Saghatelian is a Professor and Frederik Paulsen Chair at the Salk Institute for Biological Studies and an adjunct Professor at the the University of California, San Diego. Saghatelian graduate from the University of California, Los Angeles in 1997 with a degree in chemistry. He carried out organic and organometallic chemistry research on the total synthesis of a marine natural product with anti-cancer activity in the lab of Professor Craig Merlic. He earned is PhD in 2002 from the The Scripps Research Institute in Chemistry working with Professor Reza Ghadiri. During graduate school, Saghatelian worked to develop new protein and peptide catalysts through chemical synthesis and protein engineering. Saghatelian performed his postdoctoral research with Professor Benjamin Cravatt at The Scripps Research Institute where he developed novel mass spectrometry approaches for global metabolite profiling. In 2006, Saghatelian started his independent career as an Assistant Professor in the Department of Chemistry and Chemical Biology at Harvard University, and in 2014, he moved to the Salk Institute for Biological Studies. Saghatelian has published over 110 papers and six patents. Saghatelian was a recipient of the NIH New Innovator Award, a Searle Scholar Awardee, and a Sloan Foundation Fellow. Professor Saghatelian research in chemical biology merges modern analytical techniques with biochemistry and chemical biology to identify genes that regulate fundamental biological pathways and can be targeted for the development of novel therapeutics.
Salk Institute
Professor, Salk Institute
Clayton Foundation Laboratories for Peptide Biology
Dr. Frederik Paulsen Chair

Co-Founder
Prior to co-founding Exo Therapeutics in 2018, Juan Pablo Maianti earned his Ph.D. from Harvard University in Chemistry and Chemical Biology in 2015 under the supervision of Professor David Liu, following a M.Sc. in Synthetic Organic Chemistry under the supervision of Professor Stephen Hanessian at the University of Montreal in 2011, and B.Sc. in Biochemistry from the University of Canterbury in New Zealand. Dr. Maianti has been a leading author in high-impact research publications across multidisciplinary projects in chemistry, biochemistry, pharmacology, genome editing, and target validation, and is a contributor to over a dozen collaborative manuscripts as well as dozens of patents held by Achaogen Inc., Beam Therapeutics, and Exo Therapeutics. For his research contributions to the understanding of the therapeutic benefits of insulin-degrading enzyme (IDE) inhibitors in type-2 diabetes, the discovery of potent exosite-specific substrate-selective IDE inhibitors, and the development of novel broad-spectrum aminoglycoside antibiotics against ESKAPE pathogens, Dr. Maianti has been awarded The Academic Gold Medal from the Governor General of Canada in 2012, the top recognition for Canadian graduates, The Aldrich Graduate Student Innovation Award in 2013, The Knowles Award 2015 from the Gordon Research Conference, and chosen as a Talented 12 nominee by Chemistry & Engineering News in 2016.
Harvard Chemistry & Chemical Biology
C&EN Talented 12 award, Canada Academic Gold Medal

SAB Member
Stuart Schreiber’s lab studies the science of therapeutics. Researchers in his group rely on human biology to identify therapeutic targets that have been validated prior to testing in humans, and chemistry and chemical biology to discover small molecules that modulate the targets in ways required to provide relief or protection from disease.
Schreiber and his group members have discovered principles that underlie information transfer and storage in cells, specifically discoveries relating to signaling by the phosphatase calcineurin and kinase mTOR (demonstrating for the first time that drugs can result from the targeting of protein kinases and protein phosphatases), gene regulation by chromatin-modifying histone deacetylases, small-molecule dimerizers that activate cellular processes by enforced proximity, and small-molecule probes of challenging targets and processes (e.g., transcription factors, oncogenes, protein/protein interactions, transdifferentiation) that relate to human disease. Their work has contributed to diversity-oriented synthesis (DOS) and discovery-based small-molecule screening in an open data-sharing environment.
In current research, the Schreiber lab is studying the mechanisms by which cancers resist therapies by exploring a vulnerability of a cell state that group members discovered as central to resistance of many cancers to many therapies. The lab is also studying a novel mechanism our brains use to maintain brain health, and therapeutic agents that enhance the brain-protective mechanism. Each of these studies is supported by efforts to discover small-molecule “binders” that alter functions of proteins by changing their interactomes and lifetimes. The lab is using modern methods of asymmetric synthesis to yield candidate binders bearing DNA barcodes.
Broad
Core Institute Member, Broad Institute
Morris Loeb Professor of Chemistry and Chemical Biology, Harvard University
Investigator, Howard Hughes Medical Institute

SAB Member
Benjamin Ebert is an institute member of the Broad Institute, the George P. Canellos, MD, and Jean S. Canellos Professor of Medicine at Harvard Medical School, and the chair of medical oncology at the Dana-Farber Cancer Institute. He is also a Howard Hughes Medical Institute investigator.
The Ebert laboratory focuses on the molecular basis and treatment of hematologic malignancies, with a particular focus on myelodysplastic syndromes (MDS). In large-scale genetic analyses of patient samples, the lab has identified somatic mutations that predict prognosis and response to therapies in MDS patients, characterized a pre-malignant state of hematopoietic cells, and derived the molecular ontogeny of genetic lesions in myeloid malignancies. In addition to human genetic studies, the lab has elucidated the biological basis of transformation of hematopoietic cells by these somatic mutations and developed novel in vivo models to study myeloid malignancies. The lab employs genetic and small molecule screens to identify novel therapeutic targets and small molecules for the treatment of hematologic malignancies and sickle cell disease.
In collaboration with the Broad Institute Proteomics Platform, the Ebert lab elucidated the mechanism of action of lenalidomide, a derivative of thalidomide. Lenalidomide and related drugs modulate the function of an E3 ubiquitin ligase, inducing drug-dependent degradation of specific substrates that are essential for the survival of multiple myeloma and MDS cells, representing the first drugs that bind and modulate the function of an E3 ubiquitin ligase.
Ebert received a bachelor’s degree from Williams College, a doctorate from Oxford University on a Rhodes Scholarship, and an M.D. from Harvard Medical School. He completed a residency in internal medicine at Massachusetts General Hospital and a fellowship in hematology/oncology at the Dana-Farber Cancer Institute before pursuing postdoctoral research at the Broad Institute. Ebert is an elected member of the National Academy of Medicine.
DFCI, HHMI
George P. Canellos, MD, and Jean S. Canellos Professor of Medicine
Harvard Medical School Chair of Medical Oncology, Dana-Farber Cancer Institute

SAB Member
Benjamin F. Cravatt, Ph.D., is a the Gilula Chair of Chemical Biology and Professor in the Department of Chemistry at The Scripps Research Institute. His research group develops and applies chemical proteomic technologies for protein and drug discovery on a global scale and has particular interest in studying biochemical pathways in the nervous system and cancer. Dr. Cravatt is a co-founder of Activx Biosciences (acquired by Kyorin Pharmaceuticals), Abide Therapeutics (acquired by Lundbeck Pharmaceuticals), and Vividion Therapeutics. His honors include a Searle Scholar Award, the Eli Lilly Award in Biological Chemistry, a Cope Scholar Award, the ASBMB Merck Award, the Royal Society of Chemistry Jeremy Knowles Award, and memberships in the National Academy of Sciences, National Academy of Medicine, and American Academy of Arts and Sciences.
Ben obtained his undergraduate education at Stanford University, receiving a B.S. in the Biological Sciences and a B.A. in History. He then received a Ph.D. from The Scripps Research Institute (TSRI) in 1996, and joined the faculty at TSRI in 1997.
Scripps
Gilula Chair of Chemical Biology Professor

SAB Member
Charles W. M. Roberts, MD, PhD, is a leader in the field of cancer epigenetics, and his research has provided new insights into the central role of chromatin remodeling perturbations in cancer, discoveries that have been translated into investigational therapies for both pediatric and adult cancer patients. His research specifically focuses on the SWI/SNF (BAF) chromatin remodeling complex. Perturbation of this complex has broad relevance to cancer as at least nine genes that encode SWI/SNF subunits are collectively mutated in over 20% of all cancers. Roberts’ laboratory studies both the mechanisms by which SWI/SNF normally regulates chromatin structure and cell fate, and the mechanisms by which mutation of the complex drives cancer formation. Roberts is the director of the St. Jude Comprehensive Cancer Center and also serves as an executive vice president and a full member in the Department of Oncology of St. Jude Children’s Research Hospital. Roberts received his medical and doctoral degrees from Washington University School of Medicine in St. Louis, Missouri. He completed his pediatric residency and pediatric hematology/oncology fellowship at Boston Children’s Hospital/Dana-Farber Cancer Institute. Roberts has been elected to the Society for Pediatric Research, American Society of Clinical Investigation, and American Pediatric Society.
SAB Member
Director of St. Jude Comprehensive Cancer Center

CEO
Michael Bruce PhD has served as the CEO of Exo Therapeutics since early 2020. Dr Bruce has more than 20 years of drug discovery and development experience, including leadership of the development of marketed products including Bosulif and Nerlynx. Most recently, Dr Bruce was at Kaleido Biosciences (Nasdaq: KLDO) where he was a member of the deal roadshow team for the company’s IPO. Prior to Kaleido, Dr. Bruce was an early employee of CRISPR Therapeutics (Nasdaq: CRSP) where he oversaw product development and alliance management, including deals with Vertex and Bayer. Dr Bruce spent more than 12y at Wyeth and Pfizer in a variety of product development, portfolio management and clinical operations roles. Dr Bruce holds a PhD in organic chemistry from Stanford University and a BA in Chemistry from Williams College. Dr Bruce lives with his wife, a physician, and three school aged children, and entertains them with adequate guitar playing from time to time.

Novartis Venture Fund
Dr. Aaron Nelson is a Managing Director at the Novartis Venture Fund in Cambridge, MA, USA. Prior to joining NVF, he was an investor at dRx Capital, the joint investment company of Novartis and Qualcomm, focused on Digital Medicine. Previously, Aaron worked on technology strategy across multiple Business Units within Novartis, including Strategic Project Leader for the Trials of The Future program and Group Head in the Investigative Toxicology organization. Aaron studied medicine at Tufts University, cell and microbiology at the University of Pennsylvania and the Karolinska Institutet, and completed his undergraduate studies at Cornell University.

Newpath Partners
Dr. Cahill is the Founder and Managing Partner of Newpath Partners, a Boston based life science venture fund focused on building therapeutic companies around transformational scientific discoveries. Prior to Newpath, Dr. Cahill worked at Raptor Group where he helped further establish and lead the life-science and technology investment portfolio. Dr. Cahill received both his M.D. and Ph.D. from Duke University. His graduate work, with Professor Robert Lefkowitz (Nobel Laureate), focused on the biophysical and structural properties of cellular receptors and their signaling. His work has led to numerous peer-reviewed publications and awards. He continues to remain active in basic science research. Newpath is a founding investor in most of their life science companies and focuses on uniquely aligning interests between academic scientists, investors, and management teams. Dr. Cahill is directly involved as either a Director or Observer in the following companies: Myeloid Therapeutics, Prime Medicine, Kisbee Therapeutics, Kojin Therapeutics, Chroma Medicine, Exo Therapeutics, and Seven Sense Biosystems. In addition, Dr. Cahill is involved with non-profit and non-partisan groups such as Scientists to Stop COVID-19 (STSC-19) and the Personal Genetics Education Project (pgEd).

Founder and Advisor of Scholar Rock
Nagesh is a consultant and advisor to biotechnology companies, with a particular focus on start-up and early-stage ventures focused on the discovery and development of novel therapeutics. He was mostly recently the founding employee, President and CEO of Scholar Rock, Inc. During his eight-year tenure at Scholar Rock, Nagesh took the company public and lead two distinct drug candidates into clinical testing.
His previous professional experiences include being the founding employee and VP of Corporate Development at Avila Therapeutics, Inc. (acquired by Celgene in early 2012), and was previously a founding employee of Alnylam Pharmaceuticals where he rose to the position of VP, Scientific & Strategic Development. Prior roles include serving as Manager, Business Development at Vertex Pharmaceuticals, and a series of positions with increasing scientific and commercial responsibility at Ontogeny (now a part of Curis, Inc.). Nagesh started in the biotechnology industry as a Staff Scientist at Cambridge NeuroScience, and was a founder of TwistDx, a DNA diagnostics company acquired by Inverness Medical Innovations (now a part of Abbott Laboratories).
Nagesh completed his post-doctoral training at E.K. Shriver Center for Mental Retardation (then an affiliate of Massachusetts General Hospital) and Harvard Medical School after receiving his Ph.D. in Neurobiology from the California Institute of Technology. Nagesh received his B.A. in Biology and Chemistry from the University of Colorado, and his M.B.A. from the F.W. Olin Graduate School of Management at Babson College.
News

Careers

Senior/Principal Research Associate, Biochemistry
About the company
Exo Therapeutics (https://exo-therapeutics.com/) is a small molecule drug discovery and development company with a pioneering technology to address intractable pharmaceutical targets. By leveraging the company’s ExoSightTM platform, Exo is developing a deep pipeline of potent drug candidates that bind exosites, distal and unique binding pockets that have the potential to reprogram enzyme activity for precise and robust therapeutic effect. Through this specific and selective approach to challenging targets, the company’s team of world-class researchers is unlocking breakthrough therapeutics in oncology, inflammation and a broad range of other diseases.
Overview
Exo Therapeutics seeks a highly motivated Senior/Principal Research Associate with a strong background in biochemistry assay implementation and contributing to a multidisciplinary team in external and internal drug discovery activities. This position will be an integral part of the biochemistry team and will help drive the drug discovery programs forward. You will work across therapeutic functions with a primary focus in discovery and development of therapeutics in oncology, autoimmune and immuno-inflammation.
The senior/principal research associate will be expected to contribute to and complement our existing technical expertise to enhance and accelerate research. We are keen to identify someone who is a self-starter and proactive and who can work independently and effectively, both with the Exo team and external collaborators. The candidate will also participate in the build-out and maintenance of our growing laboratory environment.
Responsibilities
- Perform routine biochemical screening of compounds, eg IC50, in house or in collaboration with external partners.
- Communication and discussion of results with internal project teams, especially chemistry and biology.
- Development of novel screening assays for use either in-house or for transfer to CRO’s.
- Coordination of assay workflow locally and/or with the CRO partners, data analysis and presentation of results to the internal and external teams.
- Employ biochemical and biophysical methods enabling mechanistic studies to determine the mode-of-inhibition for promising hits.
- Propose and implement new experimental techniques and troubleshoot roadblocks in collaboration with the team.
- Independently manage and order supplies/reagents in a timely manner to ensure continuous progress of parallel experimental workflows under your responsibility.
- Management of laboratory equipment, including maintenance, vendor relations and service contracts.
- Maintain good data records, protocols, and summaries. Analyze raw data and interpret integrated datasets using Prism, Vortex, or similar software packages.
- Use of electronic lab notebook and data registration to corporate database.
- Take all opportunities to make intellectual contributions and discoveries.
Required Qualifications
- Bachelor’s degree in a life sciences-related field with by a proven track-record of hands-on laboratory experience for 4-6 years, or a Master’s degree with 4+ years of research experience, respectively.
- Strong foundation with a background in small molecule discovery/validation, biochemistry and biophysical methods.
- Proficiency in experimental design and data analysis using Graphpad Prism, Excel or equivalent software.
- Troubleshooting skills, analytical perseverance, with a strong ability to integrate advice.
- Proficiency in results presentation, data documentation, and scientific communication.
- Analyze, interpret, and effectively present scientific data at team meetings
- Ability to work effectively with flexible supervision as a member of multiple project teams
- Prior experience working with CRO partners highly preferred
- Good problem-solving skills with excellent interpersonal skills and a collaborative work style
Desired technical competencies:
- Assay development experience and capabilities such as FP, TR-FRET, AlphaScreen, etc.
- Experience in mechanistic enzymology such as Ki, mode-of-inhibition, kinetics, etc.
Other complementary and transferable skills:
- Molecular biology, protein expression, purification and characterization (for example: M/S, SEC, DLS, CD, SDS-PAGE, etc.
- Working knowledge of biophysical methods such as SPR, MST, ITC, DSF, etc.
- Familiarity with Cell-based assays (for example: BRET, iLite, DualGlo, CTGlo, HiBiT, CaspaseGlo, etc.)
All fully qualified applicants who are authorized to work in the US at the time of application will receive consideration for employment without regard to race, religion, gender, sexual orientation, national origin, ancestry, disability, veteran status, as protected under law.
To apply for the position, email a cover letter and resume to careers@exo-therapeutics.com
Sr. Scientist, Biochemistry
About the company
Exo Therapeutics (https://exo-therapeutics.com/) is a small molecule drug discovery and development company with a pioneering technology to address intractable pharmaceutical targets. By leveraging the company’s ExoSightTM platform, Exo is developing a deep pipeline of potent drug candidates that bind exosites, distal and unique binding pockets that have the potential to reprogram enzyme activity for precise and robust therapeutic effect. Through this specific and selective approach to challenging targets, the company’s team of world-class researchers is unlocking breakthrough therapeutics in oncology, inflammation and a broad range of other diseases.
Exo Therapeutics seeks a highly motivated senior scientist with a strong background in biochemistry assay implementation and contributing to a multidisciplinary team in external and internal drug discovery activities. This position will be an integral part of the biochemistry team and will help drive the drug discovery programs forward. You will work across therapeutic functions with a primary focus in discovery and development of therapeutics in oncology, autoimmune and immuno-inflammation.
The senior scientist will be expected to develop new biochemical assays and contribute to and complement our existing technical expertise to enhance and accelerate research. We are keen to identify someone who is a self-starter and proactive and who can work independently and effectively, both with the Exo team and external collaborators. The candidate will also participate in the build-out and maintenance of our growing laboratory environment.
Responsibilities
- Proposal and develop new biochemical assays for compounds testing and mechanistic studies.
- Propose and implement new experimental techniques and troubleshoot roadblocks in collaboration with the team.
- Employ biochemical and biophysical methods enabling mechanistic studies to determine the mode-of-inhibition for promising hits.
- Coordination of assay workflow locally and/or with the CRO partners, data analysis and presentation of results to the internal and external teams.
- Perform routine biochemical screening of compounds, eg IC50, in house or in collaboration with external partners.
- Communication and discussion of results with internal project teams, especially chemistry and biology.
- Independently manage and order supplies/reagents in a timely manner to ensure continuous progress of parallel experimental workflows under your responsibility.
- Management of laboratory equipment, including maintenance, vendor relations and service contracts.
- Maintain good data records, protocols, and summaries. Analyze raw data and interpret integrated datasets using Prism, Vortex, or similar software packages.
- Use of electronic lab notebook and data registration to corporate database.
- Take all opportunities to make intellectual contributions and discoveries.
Required Qualifications
• Ph.D. in biochemistry or related discipline with postdoctoral training with a proven track-record with 3+ years of industrial experience
• Strong foundation with a background in small molecule discovery/validation, biochemistry and biophysical methods.
• Proficiency in experimental design and data analysis using Graphpad Prism, Excel or equivalent software.
• Troubleshooting skills, analytical perseverance, with a strong ability to integrate advice.
• Proficiency in results presentation, data documentation, and scientific communication.
• Analyze, interpret, and effectively present scientific data at team meetings
• Ability to work effectively and independently as a member of multiple project teams
• Prior experience working with CRO partners highly preferred
• Good problem-solving skills with excellent interpersonal skills and a collaborative work style
Desired technical competencies:
- Assay development experience and capabilities such as FP, TR-FRET, AlphaScreen, etc.
- Experience in mechanistic enzymology such as Ki, mode-of-inhibition, kinetics, etc.
Other complementary and transferable skills:
- Molecular biology, protein expression, purification and characterization (for example: M/S, SEC, DLS, CD, SDS-PAGE,
- Working knowledge of biophysical methods such as SPR, MST, ITC, DSF, etc.
- Familiarity with Cell-based assays (for example: BRET, iLite, DualGlo, CTGlo, HiBiT, CaspaseGlo, et
All fully qualified applicants who are authorized to work in the US at the time of application will receive consideration for employment without regard to race, religion, gender, sexual orientation, national origin, ancestry, disability, veteran status, as protected under law.
To apply for the position, email a cover letter and resume to careers@exo-therapeutics.com
Interested in joining our team? Explore careers
Senior Scientist, Chemical Biology
About the company
Exo Therapeutics (https://exo-therapeutics.com/) is a small molecule drug discovery and development company with a pioneering technology to address intractable pharmaceutical targets. By leveraging the company’s ExoSightTM platform, Exo is developing a deep pipeline of potent drug candidates that bind exosites, distal and unique binding pockets that have the potential to reprogram enzyme activity for precise and robust therapeutic effect. Through this specific and selective approach to challenging targets, the company’s team of world-class researchers is unlocking breakthrough therapeutics in oncology, inflammation and a broad range of other diseases.
Exo Therapeutics seeks a highly motivated senior scientist with a strong background in chemical biology to work on internal target identification and drug discovery. The candidate will be responsible for tools and probes design, novel biochemical assay establishment and execution of mechanistic experiments. The desired candidate will work across a multidisciplinary team contributing to early target identification and progression of established programs across Exo portfolio.
The senior scientist will be expected to contribute and complement our existing technical expertise to enhance and accelerate drug discovery. We are keen to identify someone who is a self-starter and proactive and who can work independently and effectively, both with the Exo team and external collaborators. The candidate will also participate in the build-out and maintenance of our growing laboratory space.
Responsibilities
- Identification of protein targets, their biological pathway and mechanistic evaluation, proposal of tool and probes for biochemical assay development for cellular target validation.
- Development and application of biochemical, biophysical, and genetic methods for target-ligand engagement and validation in cell models.
- Propose and develop necessary biochemical assay and screening of compounds, eg IC50, in house or in collaboration with external partners.
- Work collaboratively with chemistry, computational chemistry, biochemistry and cell biology groups to drive the drug discovery programs forward.
- Communication and discussion of results with internal project team members across multiple disciplines.
- Coordination of assay workflow locally and/or with the CRO partners, data analysis and presentation of results in a team setting.
- Employ biochemical and biophysical methods enabling mechanistic studies to determine the mode-of-inhibition for promising hits.
- Management of laboratory equipment, including maintenance, vendor relations and service contracts.
- Maintain good data records, protocols, and summaries. Analyze raw data and interpret integrated datasets using Prism, Vortex, or similar software packages.
Required Qualifications
- Ph.D. in chemical biology or related discipline with postdoctoral training and a proven track-record with 3+ years of industrial experience.
- Strong foundation and hands-on experience in novel biochemical assay development, use of small molecule probes in target discovery/validation, biochemistry and biophysical method development.
- Track record of proposal, design, development, and execution of biological hypotheses and evaluation.
- Solid understanding of structural biology, systems biology, and molecular biology
- Excellent skillsets in appropriate programing languages, computational tools, data manipulation and visualization.
- Experience with structural biology, computational chemistry, protein homology modeling.
- Proficiency in experimental design and data analysis using Graphpad Prism, Excel or equivalent software.
- Proficiency in results presentation, data documentation, and written and oral communication.
- Work independently as apart of dynamic team of scientists with diverse expertise.
- Foster teamwork in a collaborative environment.
Other complementary and transferable skills:
- Protein expression, purification and characterization (for example: M/S, SEC, DLS, CD, SDS-PAGE,
- Working knowledge of biophysical methods such as SPR, MST, ITC, DSF, etc.
- Familiarity with Cell-based assays (for example: BRET, iLite, DualGlo, CTGlo, HiBiT, CaspaseGlo, etc.)
All fully qualified applicants who are authorized to work in the US at the time of application will receive consideration for employment without regard to race, religion, gender, sexual orientation, national origin, ancestry, disability, veteran status, as protected under law.
To apply for the position, email a cover letter and resume to careers@exo-therapeutics.com
Interested in joining our team? Explore careers
Senior/Principal Scientist, Early Target Biology
About the company
Exo Therapeutics (https://exo-therapeutics.com/) is a small molecule drug discovery and development company with a pioneering technology to address intractable pharmaceutical targets. By leveraging the company’s ExoSightTM platform, Exo is developing a deep pipeline of potent drug candidates that bind exosites, distal and unique binding pockets that have the potential to reprogram enzyme activity for precise and robust therapeutic effect. Through this specific and selective approach to challenging targets, the company’s team of world-class researchers is unlocking breakthrough therapeutics in oncology, inflammation and a broad range of other diseases.
Exo Therapeutics seeks a highly motivated biologist with a strong background in signaling pathways and their perturbations in disease. This position will be an integral part of the biology group and will help drive the identification and validation of new targets for entry into the drug discovery portfolio. You will work across therapeutic functions with a primary focus in oncology and/or immunology. The scientist will extend our existing technical expertise to enhance and accelerate our platform development. We are keen to identify someone who is a self-starter and proactive and who can work effectively with a team of multidisciplinary scientists.
Responsibilities
- Identify, evaluate, design and execute experiments for validation of novel targets in the Oncology, inflammation and immunology space
- Collaborate with colleagues within other functions in the organization to devise plans for new target triage. Work closely with the platform group to systematically evaluate targets
- Exploration of drug-target-phenotype relationships using chemical proteomics
- Phenotypic in vitro assay development, data generation and analysis, and communication to scientific team and executive management.
- Review of scientific, clinical, and patent literature to identify new target opportunities
- Help lead strategy and planning of early-stage research programs, including identifying, evaluating, and championing new ideas and technologies
- Help the biology team in identifying the relevant disease indications for the “targets” of interest
- Utilize genomics-based tools for new target identification and validation
- Develop disease relevant cellular models, using RNAi and CRISPR based tools for validating the target biology
Required Qualifications
- Ph.D. with 5-8 years of experience in cell biology or related discipline with a strong publication record. 2 to 5+ years of experience in biotech/ pharmaceutical industry
- Experience leading discovery biology efforts on project teams at various stages of the programs including target discovery/validation and lead optimization to IND-enabling studies
- Previous work leading early discovery programs with novel target identification and validation responsibilities
- Strong understanding of cancer cell signaling pathways and experience with target engagement, functional and phenotypic assays
- Experience working with genomics, human genetics, and next-generation sequencing datasets, ideally in collaboration with computational teams
- Experience in utilizing genomics-based technologies, including RNA-seq, ChIP-seq
- Experience with gene modulation techniques in cell-based studies (RNAi, CRISPR, cDNA overexpression, etc.)
- Experience with utilizing chemical biology tools and establishing biochemical assays is a plus
- Ability to work effectively as an individual and as a member of multi-disciplinary project teams and present at team meetings
- Good problem-solving skills with excellent interpersonal skills and a collaborative work style
- Excellent written and verbal communication skills
All fully qualified applicants who are authorized to work in the US at the time of application will receive consideration for employment without regard to race, religion, gender, sexual orientation, national origin, ancestry, disability, veteran status, as protected under law.
To apply for the position, email a cover letter and resume to careers@exo-therapeutics.com
Interested in joining our team? Explore careers
Senior/Principal Scientist, Translational Biology
About the company
Exo Therapeutics (https://exo-therapeutics.com/) is a small molecule drug discovery and development company with a pioneering technology to address intractable pharmaceutical targets. By leveraging the company’s ExoSightTM platform, Exo is developing a deep pipeline of potent drug candidates that bind exosites, distal and unique binding pockets that have the potential to reprogram enzyme activity for precise and robust therapeutic effect. Through this specific and selective approach to challenging targets, the company’s team of world-class researchers is unlocking breakthrough therapeutics in oncology, inflammation and a broad range of other diseases.
Exo Therapeutics seeks a highly motivated senior level scientist with a strong background in translational biology. This position will be an integral part of the biology group and will help drive the disease indication and biomarker studies to drive the programs towards the clinic. This is a leadership position, and the candidate will work across therapeutic functions with a primary focus in immunology / immuno-oncology to help discover and develop innovative therapeutics.
The individual will have experience leading the translational biology efforts for drug discovery program/s and will be expected to extend our existing technical expertise to enhance and accelerate research. We are keen to identify someone who is a self-starter and proactive and who can work independently and effectively.
Responsibilities
- Identify and validate biological contexts, in vitro and in vivo, that create a dependency of drug targets to aid indication/ context prioritization for pre-clinical studies and clinical development
- Develop program specific translational strategy that integrate preclinical research findings
- Plan and oversee in vivo PD and efficacy studies at CRO partners to support translational biology efforts
- Collaborate with drug discovery and biology teams to select disease indications for inflammation, autoimmune diseases and/or oncology targets and development of in vivo strategies
- Identify combination and differentiation strategies to help identify the right patients to treat in the clinic
- Participate in the identification and clinical translation of biomarker assays that assess drug pharmacodynamics and allow testing of preclinical response hypotheses enabling a differentiating path for drug development
- Oversee external efforts with CROs and/or academic collaborators
- Interpret, summarize and present research findings at internal and external scientific meetings
Preferred Experience and Qualifications
- Ph.D. with 5+ years of experience in biology or related discipline with a strong publication record. 2+ years in biotech/ pharmaceutical industry
- Strong understanding of inflammation/ autoimmunity signaling pathways and experience with PK/PD/efficacy studies to validate disease indications
- Experience driving translational biology efforts on project teams at various stages of the programs
- Experience in utilizing genomics-based technologies, including RNA-seq and flowcytometry based assays to identify biomarkers and to understand mechanism of action is preferred
- Experience with selection and development of in vivo disease models is preferred
- Clear and effective verbal and written communication skills
All fully qualified applicants who are authorized to work in the US at the time of application will receive consideration for employment without regard to race, religion, gender, sexual orientation, national origin, ancestry, disability, veteran status, as protected under law.
To apply for the position, email a cover letter and resume to careers@exo-therapeutics.com
Interested in joining our team? Explore careers